Last reviewed · How we verify
Lanthanum carbonate hydrate
At a glance
| Generic name | Lanthanum carbonate hydrate |
|---|---|
| Also known as | Fosrenol |
| Sponsor | Astellas Pharma Inc |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Drug Interaction Study to Evaluate the Pharmacokinetics of ASP1517 and Lanthanum Carbonate Hydrate (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lanthanum carbonate hydrate CI brief — competitive landscape report
- Lanthanum carbonate hydrate updates RSS · CI watch RSS
- Astellas Pharma Inc portfolio CI